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Abstract: Thyroid eye disease is a heterogeneous autoimmune orbital reaction typically 
manifesting in middle age. The inflammation may parallel or remain isolated from a related 
inflammatory cascade in the thyroid called Graves’ disease. The orbital manifestations can lead 
to severe proptosis, dry eyes, strabismus, and optic neuropathy. In this article, we will discuss 
this unique condition including the ophthalmic findings and management.
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Pathogenesis and epidemiology
The overwhelming majority (90%) of thyroid eye disease (TED) cases are associated 
with hyperthyroidism, while the rest are either euthyroid or hypothyroid.1 Cross-
reactivity against shared antigen(s) in thyroid and orbital tissue is most likely 
responsible for the autoimmune ophthalmologic reaction. Antibodies involving the 
thyroid-stimulating hormone (TSH) receptor may drive the pathogenesis of this 
inflammation.2 Autoreactive T lymphocytes migrate into the orbital soft tissue, fat and 
musculature reacting with the shared thyroid and orbital antigen(s). The inflammation 
results in anatomical changes including eyelid retraction (NOSPECS class I) and 
redness and swelling of periorbital tissues (class II) including the eyelids, conjunctiva, 
and caruncle.3,4 Secretion of a cytokine cascade stimulates fibroblast proliferation and 
secretion of glycosaminoglycans resulting in proptosis (class III) from retro-orbital 
fat expansion and extraocular muscle swelling. The expansion of orbital tissues may 
lead to the severe motility disorders (class IV), corneal exposure (class V) and optic 
nerve damage (class VI). Eventually this process results in fibrosis of the extraocular 
musculature and permanent restriction of eye and lid movements.
Both endogenous (genetic factors, increased age, male sex) and exogenous factors 
(smoking, thyroid dysfunction, and radioiodine treatment) likely contribute to the 
development or severity of TED.5,6 Approximately half of Graves’ disease patients 
experience ophthalmic manifestations, with sight-threatening disease in 3% to 5% 
of cases.7 The heterogeneous manifestations and variable course of TED may greatly 
affect the quality of life in affected patients.
Although TED is a heterogeneous genetic disorder, finding a common genetic loci 
remains elusive. Candidate genes include human leukocyte antigen (HLA, 6p21–3), 
cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumor necrosis factor (TNF, 6p21–3), 
interferon-γ, 12q14), intercellular adhesion molecule-1 (ICAM-1, 19p13), and thyroid Clinical Ophthalmology 2009:3 544
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stimulating hormone receptor gene (TSH-R, 14q13).5 TED 
exhibits a female to male ratio of 4:1; however, more severe 
disease occurs among affected elderly males.8
Course of disease
Thyroid eye disease typically has an inflammatory, active 
phase subsiding over one to two years (range 6 months to 
5 years) into a fibrotic, inactive phase (Figure 1).9 After 
the inflammation subsides, patients may suffer permanent 
structural changes around the eyes requiring treatment. Active 
inflammation recurs in about 1% of patients after months to 
years of inactivity. Unfortunately, no reliable test or sign exists 
to determine when the inactive phase has begun. These patients 
return for repeat evaluations to document changes in symptoms 
or clinical findings. Stable clinical findings for 6 months 
suggest that the patient has passed from the active to the inac-
tive phase. It is important to recognize every patient’s course 
of TED is different and unique. Some may have minimal signs 
while others have sudden onset of severe complications such 
as severe diplopia, proptosis and vision loss.
Smoking has a strong relationship with the course and 
severity of thyroid eye disease. The relationship is dose-
responsive between cigarette use and probability of developing 
thyroid eye disease.10 Smoking is associated with an increased 
risk of ophthalmic disease after radioiodine therapy and worse 
or delayed outcomes for treatment of thyroid eye disease.11
Clinical findings
Ophthalmic findings are generally bilateral, but may present 
unilaterally or asymmetrically.1 The presence of pre-existing 
autoimmune thyroid disease increases suspicion for TED, but 
isolated eye findings may represent the presenting manifestations 
of thyroid disorders. The classic presentation in the setting 
of acute Graves’ disease involves thyrotoxicosis, goiter and 
bilateral exophthalmos. In one cohort of 120 TED patients, 
clinical features included: eyelid retraction 91%, exophthalmos 
62%, extraocular muscle dysfunction 43%, ocular pain 30%, 
lacrimation 23%, and optic nerve disease 6%.12
The earliest findings in TED usually involve mild soft 
tissue inflammation. Early symptoms include foreign body 
sensation, excessive tearing from dry eye, conjunctival or 
eyelid redness and swelling, blurred vision, and retro-orbital 
pain. Dilated conjunctival vasculature, keratoconjunctivitis, 
and corneal staining may be seen on slit lamp examination.
As the orbital inflammation progresses in severity, 
swelling of the extraocular muscles (EOM) or orbital soft 
tissue often manifests as chemosis, lid edema and ocular 
proptosis.13 The EOM may become visible as blood vessels 
over their anterior portion show prominence. Such vessel 
engorgement overlying the lateral rectus has been described 
as a sign of activity;14 however this may persist during the 
inactive disease phase.13 Poor venous drainage secondary to 
the congestive mass effect behind the eyes may contribute 
to redness and swelling of the eyelids, conjunctiva, and 
caruncle. Involvement of the levator palpebrae results in 
eyelid retraction and the characteristic “stare” of TED 
(Figure 2). This appearance is often exaggerated by the 
presence of exophthalmos. Progressive proptosis with eyelid 
retraction and meibomian gland inflammation may worsen 
corneal exposure and progress to corneal ulceration and 
perforation.15,16 Inflammation and scarring of the EOM can 
cause strabismus and ophthalmoplegia. In mild cases, patients 
might feel a pulling sensation around the eyes. With more 
advanced disease, horizontal, vertical and torsional strabismus 
and double vision ensues (Figure 3). Asymmetric EOM 
restriction manifests as incomitant deviations with diplopia 
in eccentric gazes, ie, sidegaze esotropia or upgaze hypot-
ropia with medial or inferior involvement respectively. In 
severe cases the restrictive, incomitant strabismus occurs 
in primary gaze and patients complain of constant double 
vision. In addition to vertical and torsional tropias, inferior 
rectus involvement may lead to a poor Bell’s phenomenon 
with increased risk of corneal exposure. Diffuse orbital and 
EOM restriction may lead to intermittent spiking or chronic 
elevation of intraocular pressure. Intraocular pressures should 
regularly be tested in both primary and upgaze. Strabismus 
may develop at any stage in the disease or secondary to 
orbital changes after decompression surgery. In addition, 
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Figure 1 rundle’s curve mapping increase in disease activity or severity followed by 
a reduction over time.Clinical Ophthalmology 2009:3 545
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vertical rectus strabismus surgery may cause iatrogenic eyelid 
retraction and worsen corneal exposure.
With severe inflammation, the expansion of soft tissues 
confined within the bony orbit and swelling of the muscles 
at the apex of the orbit may compress the optic nerve 
causing dysthyroid optic neuropathy (Figure 4).17 Although 
early symptoms include progressive blurring of vision and 
fading of colors in one or both eyes, visual acuity may be 
preserved in a minority of patients with optic neuropathy.18 
Of note, when optic neuropathy occurs the degree of proptosis 
often does not correlate. Presumably, this occurs when the 
enlarged EOM expand to compress the optic nerve instead 
of producing exophthalmos. Signs of optic neuropathy 
include decrease in visual acuity, visual field, and color vision 
along with the development of an afferent pupillary defect. 
Bilateral, simultaneous optic neuropathy can occur which 
would eliminate a relative afferent pupillary defect. The 
optic disc may be normal or edematous. Without detection 
through serial screenings and subsequent prompt treatment, 
permanent optic atrophy and visual loss may occur.
Careful evaluation of TED patients presenting to an 
ophthalmologist allows for quantitative assessment disease 
activity and severity.17 Activity of thyroid eye disease can 
be assessed with the Clinical Activity Score (Table 2).19 
The clinical features of inflammation are graded based 
upon comparison with photographs to improve objectivity.17 
Severity may be assessed using the NOSPECS classification; 
this mnemonic for evaluation assists in differentiation of mild, 
moderate, and severe disease (Table 1).3,20 Impairment of 
quality of life can be elicited with the Graves’-ophthalmopathy 
specific QOL questionnaire (GO-QoL).21 Initial laboratory 
studies include bloodwork for thyroid stimulating hormone 
(TSH), thyroid stimulating immunoglobulin (TSIG), thyroid 
peroxidase (TPO) antibody, and TSH receptor antibody.
Lastly, radiographic imaging using CT, MRI, or 
ultrasound may aid in the diagnosis of thyroid eye disease. 
CT scanning is the modality of choice to evaluate dysthyroid 
optic neuropathy and the planning of surgical intervention. 
Findings often include enlargement of orbital fat or 
musculature with sparing of insertions. The inferior and 
medial recti are most commonly affected. Other finding 
on imaging include intracranial prolapse of fat through the 
superior orbital fissure, straightening of the optic nerve or 
impingement of apical musculature on the optic nerve.
The differential diagnosis for the clinical features of 
thyroid eye disease includes infectious and inflamama-
tory orbital conditions such as orbital myositis, idiopathic 
orbital inflammatory syndrome, and orbital cellulitis. Rarer 
conditions include orbital neoplasms and carotid artery – 
cavernous sinus fistulas. New onset diplopia may result from 
cranial nerve palsies, internuclear ophthalmoplegia, or 
myasthenia gravis.
Management
Patients with Graves’ ophthalmopathy should be managed 
by a coordinated team of primary care physicians, 
Figure 2 Severe inflammation and proptosis with classic “stare” of thyroid eye disease 
may be prominent in the active phase of disease.
Figure 3 esotropia strabismus is a common manifestation of medial rectus enlargement 
in thyroid eye disease.
Figure 4 CT imaging of extraocular muscle enlargement at orbital apex.Clinical Ophthalmology 2009:3 546
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endocrinologists, and ophthalmologists with specialty 
experience in managing TED. This typically involves a 
neuro-ophthalmologist, an orbital surgeon, and a strabismus 
surgeon. The complicated nature of treatment often requires 
coordination of medical, surgical and radiation therapy.22 
Uncontrolled thyroid function is associated with more severe 
thyroid eye disease.23,24 However, antithyroid drugs and 
surgical subtotal/near-total thyroidectomy therapies typically 
do not improve the ophthalmic disease course.25,26 In fact, 
radioiodine therapy for Graves’ disease can exacerbate oph-
thalmic disease; particularly in the context of smoking, active 
disease, or elevated TSH-receptor autoantibodies.27,28 Admin-
istration of steroids during and following radioiodine therapy 
decreases the risk of exacerbation in patients with active 
TED.29 When radioiodine is administered to patients with 
inactive TED, risk of eye disease exacerbation is minimal.30
Ophthalmologic treatment must be tailored to the patient’s 
quality of life,psycho-social effects, and severity and stage 
of disease. Smoking cessation is mandatory in all phases 
because it worsens outcome and represents a modifiable 
risk factor.31 Mild, early disease does not require surgical or 
immunomodulating therapy and clinicians may choose to wait 
and monitor signs. Management can be symptomatic with 
lubricating eye drops and ointments for corneal exposure 
and temporary prisms for diplopia.32 Serial examinations 
are necessary to screen for progression of disease and 
determination of stability. Moderately severe or severe 
worsening of orbital congestion and/or severe proptosis can 
occur with concurrent dysthyroid disease or many years after 
well-controlled thyroid function from Graves’ disease. When 
sight is threatened from optic neuropathy or corneal break-
down, urgent referral is necessary to initiate “rescue” therapy, 
often with glucocorticoid administration and/or orbital 
decompression. Once the chronic inflammation associated 
with TED becomes quiescent and a period of stability is noted, 
“rehabilitative” surgical therapies may be considered.
Rescue therapy
When moderate to severe TED is present, early “rescue” 
intervention may be indicated. Indications for “rescue” 
include evidence of optic neuropathy, signficant proptosis and 
extensive exposure keratopathy. Urgent “rescue” treatment, 
either alone or a combination, includes corticosteroids, 
surgical orbital decompression, and orbital radiation.
Severe thyroid eye disease is often treated initially with 
glucocorticoids. The efficacy and tolerability of intravenous 
administration (IV) is superior to oral or local injection. Oral 
glucocorticoids, typically prednisone 60 to 100 mg/day, 
must be taken over an extended period of time.33,34 With 
oral glucocorticoids, bisphosphonates should be considered 
Table 1 Clinical activity or severity may be assessed with either the Clinical Activity Score (CAS) or the NOSPeCS severity assessment
Clinical Activity Score (CAS)
Score determined by sum of the symptoms 
and signs in a patient with TeD at a given visit
Spontaneous retrobulbar pain
Pain on attempted up-gaze or down-gaze
redness of the eyelids
redness of the conjunctiva
Swelling of the eyelids
Inflammation of the caruncle and/or plica
edema of the conjunctiva
NOSPECS Severity Assessment
Class 0 No signs or symptoms
Class 1 Only signs, no symptoms Lid aperture (mm)
Class 2 Soft tissue involvement Swelling, redness
Class 3 Proptosis exophthalmos (mm)
Class 4 extraocular muscle 
involvement
Ductions (degrees), diplopia score (0, no diplopia; 
1, intermittent: diplopia in primary position of gaze 
when tired or awake; 2, inconstant: diplopia at 
extremes of gaze; 3, constant: diplopia always present)
Class 5 Corneal involvement Punctate keratopathy, ulceration
Class 6 Sight loss Optic nerve involvement: changes in visual acuity, 
color vision, visual fields, or optic diskClinical Ophthalmology 2009:3 547
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for limitation of osteoporosis.35 Intravenous glucocorticoids 
pulse therapy may be more effective and better tolerated than 
oral glucocorticoids.36 Marcocci et al found optic neuropathy 
improved in 11 of 14 patients receiving IV steroids vs 3 of 9 
taking glucocorticoids orally. Additionally, the final Clinical 
Activity Score convalesced IV as compared to the oral 
glucocorticoid treated group. Improvement in symptoms 
generally occurs after 1 to 2 weeks of high dose intravenous 
glucocorticoids.37 Rarely adverse effects have included 
reports of acute liver damage and failure at high doses.38 
For this reason, it is recommended to confine the cumulative 
glucocorticoid dose to less than 8 g39 (Table 2).36,40,41
Alternatively, some surgeons feel intraorbital injection of 
glucocorticoids provide relief of ophthalmologic symptoms 
with minimal systemic side effects.34 A dose of 20 mg 
triamcinolone (Kenalog® 40 mg/mL) monthly is injected 
into the inferior lateral quadrant of the orbit. There is 
disagreement,42 however, between data comparing injections 
to other forms of steroid administration.43
Orbital decompression has been a mainstay in historical 
treatment for TED. Medical therapies have come to replace 
surgical for the initial management of certain cases of 
dysthyroid optic neuropathy although both are efficacious.44 
When contraindications exist to medical management or 
disease is refractory to trial of glucocorticoids and radiation, 
urgent surgical decompression is necessary. Decompression 
for optic neuropathy traditionally involves removal of 
the medial and inferior walls.45 Access to these structures 
is achieved through transconjunctival or transcaruncular 
incisions. Otolaryngology may also decompress the posterior 
medial orbit through a transphenoidal approach. Removal 
of sufficient posterior bone is important for decompressing 
optic neuropathy.
The use of botulinum toxin for dysmotility in TED 
was first described by Scott.46 Early in the disease course, 
a botulinum extraocular muscle injection may temporarily 
improve motility. However as the disease progresses and the 
musculature becomes more fibrotic, lasting effects are often 
limited. Botulinum administration to the levator complex 
has been shown to temporarily improve lid retraction and 
corneal exposure.47
The data surrounding use of external ionizing orbital 
radiation is mixed. Clinical application of such therapy 
for dysthyroid optic neuropathy lacks conclusive support. 
Orbital radiation in the active disease phase showed 
no efficacy in one report.48 Radiation is equally as 
effective as oral glucocorticoids,49 yet the combination 
of treatments provide better results than either individual 
therapy.50 In trials approximately 60% of patients respond to 
radiation.51 A recent report reviewing orbital radiation found 
improvement in extraocular motility; however, no evidence 
of improvement in proptosis, eyelid retraction, or soft tissue 
swelling.52 Lower doses of radiation, 1 Gy per week for 
20 weeks, have been shown to be equally effective and better 
tolerated than higher doses, 20 Gy per orbit over 2 weeks.53,54 
Safety of orbital radiation is encouraging; new onset of 
definite radiation retinopathy is 1% to 2% over 10 years.55 
Absolute contraindications include diabetic retinopathy and 
severe hypertension, while young age represents a relative 
contraindication.56 Fortunately, radiation therapy does not 
appear to compromise future surgical therapies.57
Rehabilitative surgical therapy, as described below, is 
best initiated after six months of stable, inactive thyroid 
eye disease.58 If decompression surgery is performed in the 
active phase, additional decompression may be necessary 
due to inflammatory changes that persist post-operatively. 
Additionally, spontaneous remission of symptoms is possible 
with resolution of the active phase. Wise timing could, 
therefore, spare patients from unnecessary procedures.
Rehabilitative surgical therapy
Rehabilitative surgical therapies are implemented for stable, 
inactive TED. Such surgical therapy typically involves orbital 
decompression, strabismus surgery, eyelid repositioning and 
blepharoplasty. Patients with mild disease may only require 
one of these restorative procedures. Conversely, patients with 
severe disease may require all three types of surgery in suc-
cession as needed. The order of these procedures is important 
because decompression may alter or create strabismus, and stra-
bismus surgery on vertical recti can alter eyelid positioning.
Orbital decompression surgery
Traditional indications for decompression involved 
predominantly optic neuropathy and severe exposure 
keratopathy. Currently medical therapy including external 
beam radiotherapy may be considered prior to decompression 
Table 2 Proposed methyprednisolone dosing regimens
Author Proposed methylprednisolone dosing regimen
Kahaly40 iv methylprednisolone once weekly; 0.5 g, then 0.25 g,  
6 wk each (4.5 g total)
van Geest41 iv methylprednisolone 500 mg, over 3 consecutive days, in 
4 cycles at 4 weekly intervals (6 g total)
Marcocci42 iv methylprednisolone; 15 mg/kg for 4 cycles and then 7.5 
mg/kg for 4 cycles; each cycle consisted of 2 infusions on 
alternate days at 2-week intervals (9 to 12 g total)Clinical Ophthalmology 2009:3 548
Bothun et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
for optic neuropathy. Proptosis has expanded as a surgical 
indication to include decompression for cosmesis; and 
decompression is often utilized to provide relief of congestion. 
Orbital decompression involves either removal of or thin-
ning of any combination of orbital wall surfaces in addition 
to removal of orbital fat. In bony decompression, additional 
space is created for soft tissues to prolapse, often into the 
ethmoid or maxillary sinuses, temporal fossa, and/or cranial 
cavity. Removal of the inferior wall with the medial, inferome-
dial and lateral, balanced medial and lateral, and deep lateral 
wall decompression are common techniques. Alteration of the 
orbital vault structure can lead to new onset of diplopia.
In patients lacking diplopia before surgery a medial and 
lateral balanced decompression has been advocated. The 
objective of this technique is to decrease morbidity includ-
ing hypoglobus and imbalanced motility. Endoscopic medial 
and external lateral technique has been shown to provide 
effective orbital decompression and compares favorably to 
3-wall decompression.59
Deep lateral wall decompression has reportedly reduced 
proptosis as much as 6 mm. (Figures 5, 6) Lateral wall 
decompression alone has a low rate of new onset diplopia 
of approximately 7%, with reports as low as 2.6%.39 
Complications of deep lateral decompression include 
cerebrospinal fluid leaks. A volume expansion of 5.6 cc 
may be achieved with this procedure alone.60 Deep lateral 
decompression may also be combined with removal of other 
walls as needed.
Fat decompression
Removal of intraconal fat reduces congestive orbitopathy, 
proptosis, and may improve preoperative diplopia. Selec-
tion of patients is important and CT or MRI is useful in 
assessing those with predominantly fatty or muscular soft 
tissue enlargement.61 Patients with orbital fat expansion 
experience better outcomes from fat-only decompression than 
patients with predominantly extraocular muscle enlargement. 
Decompression typically involves the inferolateral and 
superomedial compartments with removal of 3–6 cc of 
intraconal fat. Safety has been verified with proper selection 
of patients with orbital fat volume expansion, and new onset 
diplopia is rare.62 Intraconal fat debulking may be utilized 
alone or in combination with bony decompression.
Strabismus
Thyroid eye disease patients often develop diplopia and 
strabismus requiring surgical correction. The restrictions in 
motility are most commonly hypotropia or esotropia caused 
Figures 5 (left) and 6 (right) Pre- and post-operative orbital decompression images document a marked decrease in proptosis.
Figures 7 (left) and 8 (right) Pre- and post-operative strabismus surgery images document improvement of motor alignment.Clinical Ophthalmology 2009:3 549
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by inferior and medial rectus involvement respectively. 
Strabismus may present with the onset of orbitopathy or 
as a direct result of decompression surgery. Patients with 
preoperative diplopia undergoing inferior and medial wall 
decompression may experience worsening.63 Surgical 
correction of strabismus is, therefore, planned after 
decompression. The primary goal of strabismus surgery 
in TED is restoration of single binocular vision in primary 
gaze and reading position. (Figures 7, 8) Managing patient 
expectations is important and the surgeon should counsel 
that single binocular vision in all fields may not be possible. 
Resection of extraocular muscles is rarely recommended 
due to the fibrosis and restriction of musculature. Muscle 
recession on adjustable sutures are frequently utilized since 
results are more unpredictable compared to the pediatric 
population.64 A single surgery functions sufficiently in 85% 
of cases with reoperation or prism use in the remainder.65 
Approximately 25% of all TED patients use prisms or adopt 
an abnormal head positioning after surgery.
eyelid repositioning and blepharoplasty
Surgery for lengthening eyelids and reducing retraction 
is frequently performed for patients. Benefits include 
improvement in symptoms of corneal exposure and appear-
ance. Eyelid repositioning should take place after orbital 
decompression and strabismus surgeries since vertical rectus 
surgery may alter eyelid position.66 (Figures 9, 10) Patients 
with TED often develop significant fatty prolapse and derma-
tochalasis of the eyelids requiring blepharoplasty. This proce-
dure may be performed in concert with eyelid repositioning, 
but often is performed later as a separate procedure.
Future therapies
Controversial  therapies  include  a  variety  of  other 
immunomodulatory agents. Cyclosporine has been shown 
to work synergistically when used with glucocorticoids.67 
Other research suggests that agents including rituximab and 
etanercept may be beneficial.68,69 Agents with less proven value 
include azathioprine, ciamexone, iv immunoglobulin, and 
somatostatin analogs. There is hope for future use of therapies 
targeting the immune system and the pathophysiologic 
mechanism of thyroid eye disease, however, no conclusive 
data yet exists.
Summary
Patients with thyroid eye disease necessitate serial examina-
tions and at times intensive specialty care for the ocular mani-
festations of this disfiguring and potentially blinding disorder. 
At the University of Minnesota such care is orchestrated by 
the Center for Thyroid Eye Disease where patients are cared 
for at each clinical visit by a neuro-ophthalmologist, orbital 
and oculoplastic surgeon, and strabismologist. Through this 
multispecialty approach, the patient’s strategic management 
and outcome are maximized.
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